Taking a look at stock we notice that its last check on previous day was $39.90 and 5Y monthly beta was reading 0.424 with its price kept floating in the range of $39.59 and $40.755 on the day. Considering stock’s 52-week price range provides that VRNA hit a high price of $40.13 and saw its price falling to a low level of $11.39 during that period. Over a period of past 1-month, stock came adding 16.70% in its value.
With its current market valuation of $3.27 billion, Verona Pharma Plc ADR is set to declare its quarterly results in December. Analysts are in estimates of -0.25 per share for company’s earnings in the current quarter and are expecting its annual EPS growth moving up to -2.16 for current year with estimates of that growing to -0.76 in next year.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Analysts watching the company’s growth closely have provided estimates for its revenue growth with an average revenue estimate of 12.89M. They suggested that in the process company could generate revenue of as low as 9.11M which could climb up to 17.21M to hit a high.
In contrast, when we review VRNA stock’s current outlook then short term indicators are assigning it an average of 100% Buy, while medium term indicators are categorizing the stock at an average of 100% Buy. Long term indicators are suggesting an average of 100% Buy for it.
According to ratings assigned by 7 analysts at the scale of 1 to 5 with 1.00 representing a strong buy and 5.00 suggesting a strong sell; 0 of them are recommending Verona Pharma Plc ADR (VRNA) as a Hold, while 7 are in view that stock is a Buy. Recommendation by 0 analysts for the stock is an Underweight while number of those analysts who rated the stock as an Overweight is 0, whereas 0 of them are considering the stock as a Sell. When taken as whole, stock gets a rating of Overweight and that encourages the investors to exploit the opportunity and build their stake up in the company.
Digging deeper we become aware of the PEG ratio of the VRNA stock which is currently positioned at 0. It further provides that stock’s current price level is 4.92% away from its 20-day simple moving average and is 15.79% off its SMA50. Its relative strength index (RSI) for 14-periods is oscillating at 64.00 while volatility remained at 2.86% over the past week which changes to 5.28% when measuring it over the past month. Beta is valued at 0.46, while measure of average true range or ATR is currently at 1.62. In predicting price targets of as low as $26 and as high as $42, analysts are in agreement on assigning the stock over the next 12 months average price target of $36. Stock’s current price level is 34.84% above from estimated low price target while it is -5.26% below the estimated high; and even if the VRNA’s share succeeded to reach the median price of $36, then the outlook of 9.77% could come to the excitement of the investors.
Having a second look at Verona Pharma Plc ADR (NASDAQ:VRNA) provides that stock’s average daily trading volume for 3 months was 1.04 million, while it jumped to 1157020 when we calculate an average volume for past 10 days. Number of outstanding shares of the stock stood at 80.44 million.
The percentage of outstanding shares held by the insiders is 15.90% while it is 67.16% for the institutional holders. The figures also indicate that as of 2024-11-15, number of stock’s short shares was 5.98 million which implies a short ratio of 5.78. This shows down a 763.00 of Short Interest in company’s outstanding shares on the day. In November the standing of shares short improved as it was 7.94 million in the previous month. Addition of 100.70% by stock’s current price to its year-to-date value in last trading session is likely to be increasing investors’ interest in the stock as it is hinting an extended uptrend.
